On September 3, 2026, clinical trial technology provider Medidata gathered pharmaceutical executives in Shanghai for its NEXT China annual conference. The message was blunt: the era of scattering artificial intelligence across a study as a loose collection of disconnected tools is ending. What comes next is a single, unified platform that runs the entire trial.
The shift reaches far beyond one company’s product launch. It marks a turning point in how AI is applied to clinical trials, one of the most expensive and failure-prone stages in all of medicine. It also explains why a conference about the future of drug development was staged in China, where regulators are rewriting the rules to fold AI into the approval process itself.
This report explains what a unified AI clinical trial platform actually is, why fragmented “single-point” tools have run into hard limits, and why the transition is accelerating fastest in China.
Why Clinical Trials Are AI’s Hardest Problem
Drug discovery attracts most of the AI headlines, but the trial stage is where the money and the risk concentrate. Historically, roughly 90% of candidate drugs that entered clinical development failed there, undone by safety concerns or insufficient effectiveness.
The operational waste is just as striking. Medidata disclosed in Shanghai that about 11% of research sites ultimately fail to enroll a single patient. Each of those sites consumes budget, staff time, and months of planning without producing usable data. For sponsors working in hard-to-recruit populations, the gap between plan and reality can decide a study’s fate.
Much of that loss begins before the first participant is ever recruited. Building the digital backbone for one trial, meaning the case report forms, visit schedules, and validation rules that flag data errors, traditionally took 10 to 12 weeks.
The Limits of Single-Point AI Tools
The first wave of AI in clinical trials arrived as a set of narrow specialists. Large language models read medical records. Matching engines paired patients with suitable studies. Other tools sorted adverse event reports and screened scientific literature.
Each solved a genuine problem, and together they created a new one. Data ended up scattered across separate systems, which raised integration complexity and multiplied the number of vendors a sponsor had to manage.
- Fragmented data: insights produced in one tool rarely flow cleanly into another.
- Integration overhead: every added tool is another interface to build and maintain.
- Vendor sprawl: sponsors juggle contracts, security reviews, and support across many providers.
- Lost context: a model that reads patient records cannot act on what a scheduling tool knows.
That last point is the real ceiling. Artificial intelligence performs best when it can reason across connected information. Spread the information out, and the intelligence thins with it.
What a Unified AI Trial Platform Actually Does
Medidata’s response is Medidata Plus, an AI platform architecture launched in July 2026 that spans the entire clinical trial process. At its center sits Dot, described as an AI orchestration engine that connects the research, patient, and data experience into a single collaborative workflow.
The Shanghai launch was first reported in detail by the Chinese business outlet 36Kr, whose coverage of the event is the source for several of the figures below.
The scale behind the platform is the point. The company says it has cumulatively supported more than 38,000 clinical trials involving 12 million participants and that it has signed data rights agreements with more than 90% of its clients, permitting compliant use of operational data to train its models.
The clearest demonstration came in database construction. In Shanghai, staff uploaded a trial protocol as a PDF. The system extracted the visit schedule and evaluation plan, generated the forms and validation rules, and assembled test data on its own. Work that normally takes 10 to 12 weeks can be compressed into days.
The company also says its AI has been applied to more than 500 clinical studies over the past decade, a history that gives its models a deep well of trial behavior to learn from.
| Dimension | Single-point AI tools | Unified AI platform |
|---|---|---|
| Data | Scattered across vendors | Centralized and shared |
| Integration | Custom-built per tool | Built into one architecture |
| Vendor management | Many contracts and reviews | Single orchestration layer |
| Study build | Manual, 10 to 12 weeks | Automated, completed in days |
| Simulation | Limited or absent | Protocol test runs before enrollment |
| Typical example | Standalone matching or coding tools | Medidata Plus with Dot |
Trial Simulation: Rehearsing a Study Before It Runs
Perhaps the most consequential capability is simulation. Before a single patient is enrolled, a clinical team can repeatedly “test run” a protocol inside the platform. It can ask what happens if one inclusion criterion is relaxed or how changing the mix of research sites shifts recruitment speed, cost, and completion time.
The system compares those variables against the actual performance of similar historical trials and predicts where a protocol is likely to stumble. Problems that once surfaced only after launch, and after significant capital had been committed, can now be found during planning.
“We want you to know how the trial will run before it actually runs,” said Jeff Ventimiglia, Medidata’s senior vice president of operations and transformation, at the event.
Why This Shift Is Happening in China First
Medidata chose Shanghai to stage its China conference for a reason: China has become one of the world’s most active markets for clinical research, and its regulators are moving unusually fast to build AI into the system. China’s rise also fits a broader pattern of research globalising beyond traditional Western hubs, a shift already visible in the growth of clinical trials in Eastern Europe.
In April 2026, the National Medical Products Administration issued its Implementing Opinions on “Artificial Intelligence + Drug Regulation”. The policy sets two phased goals, aiming by 2030 to establish an integrated innovation system that combines drug regulation with AI, supported by high-quality datasets and dedicated models built for regulatory work.
A revised Good Clinical Practice guideline took effect on September 1, 2026, adding explicit provisions on data governance and requiring that new technologies be applied in line with ethical and scientific standards. Separately, Order 818, effective May 1, 2026, created a parallel pathway for the clinical translation of advanced biomedical technologies, from cell therapies to brain-computer interfaces. That parallel pathway reflects a wider global debate over how regulators handle personalized medicine, where traditional approval frameworks struggle to keep pace.
The same regulator has simultaneously tightened scrutiny of investigator-initiated trials, tying faster adoption of AI to stricter expectations for data quality. The pattern is deliberate: accelerate the tools and raise the bar for the evidence they produce.
How the West Is Racing to Catch Up
The unified platform idea is not confined to China. Western vendors are pursuing the same consolidation, often with measurable results.
On September 3, 2026, the same day as the Shanghai conference, IQVIA unveiled its Predictive Clinical Development platform. The company reported 33% faster study startup, 1.7 times more patients recruited from AI-prioritized sites, 42% higher enrollment rates, 50% faster data cleaning, and a reduction of more than 45% in the time between trial phases.
Individual drugmakers are reporting similar gains. The industry’s biggest players have been investing in AI drug development for years, and those bets are now reaching the trial stage. Reuters reported that Novartis compressed its trial site selection process from a four-to-six-week exercise into a two-hour meeting and that companies such as GSK are using AI to cut manual data collection and aggregation.
Regulators are adapting too. In April 2026, the U.S. Food and Drug Administration launched a pilot to review data in real time from trials run by AstraZeneca and Amgen and invited public input on using AI for safety monitoring and patient recruitment. The pressure to move faster is reshaping review work itself, which is why regulatory intelligence has become a discipline in its own right across drug and device approvals.
This work builds on a longer track record of AI in life sciences. IL has covered how specialized life sciences AI is compressing drug discovery timelines and how AI is reshaping medical product innovation more broadly.
The AI in the Clinical Trials Market Is Exploding
Analysts disagree on the exact size of the market, but not on its direction. Forecasts cluster around strong double-digit annual growth through the early 2030s, with Asia Pacific named as the fastest-growing region.
Fortune Business Insights values the global AI in clinical trials market at USD 5.5 billion in 2026 and projects it will reach USD 77.3 billion by 2034, a compound annual growth rate of 39.14%. Firms such as Mordor Intelligence offer more conservative figures, yet all point the same way.
| Research firm | 2026 market size | Forecast | CAGR |
|---|---|---|---|
| Fortune Business Insights | $5.5 billion | $77.3 billion by 2034 | 39.14% |
| Mordor Intelligence | $2.68 billion | $8.24 billion by 2031 | 25.19% |
| BCC Research | $2.4 billion | $6.5 billion by 2030 | 22.6% |
How AI Is Used Across a Clinical Trial Today
Taken together, these platforms now touch nearly every phase of a study, not just the laboratory work that produces a candidate molecule. They are part of a wider wave of AI capabilities reshaping the medical field.
- Protocol design: models analyze past trial successes and failures to suggest inclusion criteria, sample sizes, and study durations that are more likely to succeed.
- Site selection: algorithms predict which research centers will recruit well, replacing guesswork that leaves about 11% of sites with no patients at all.
- Patient recruitment: AI-matched outreach identifies people most likely to meet study criteria and keeps enrollment on schedule.
- Data management: automated study builds and real-time cleaning cut weeks of manual setup and error checking, building on the foundations of clinical trial data management.
- Safety monitoring: language models scan adverse event reports and flag signals for human review.
- Regulatory submissions: AI drafts regulator-ready documentation, shortening the path from final data to filing.
The Risks and Open Questions
Faster trials are not automatically better trials. The same consolidation that makes AI more powerful also concentrates enormous influence over how studies are designed and run inside a small number of platform providers.
- Data governance: training models on trial operations depends on broad data rights agreements, which raise consent and privacy questions.
- Bias: models trained on historical trials can reproduce the blind spots of those trials, particularly in underrepresented populations.
- Regulatory acceptance: agencies still want to see how algorithmic decisions were reached, which pushes platforms toward explainable outputs.
- Overreliance: simulation can reduce risk, but it cannot substitute for real-world evidence.
These are the same tensions that surface across responsible AI generally, where capability tends to outrun governance.
China’s approach hints at how regulators may respond. Its new policy pairs rapid AI adoption with stricter data governance and tighter oversight of early-stage trials, treating speed and rigor as a package rather than a trade-off.
Frequently Asked Questions
How is AI being used in clinical trials?
AI is used across the full trial lifecycle. It helps design protocols, predict which research sites will recruit successfully, match patients to studies, automate the construction of trial databases, clean and validate data in real time, monitor safety signals, and draft regulatory submissions.
Which AI companies are leading in clinical trials?
The strongest positions belong to companies with deep trial data and existing workflow integration, rather than to standalone AI startups. Medidata, which has supported more than 38,000 trials, and IQVIA, which launched its Predictive Clinical Development platform in September 2026, are among the most prominent. CROs such as Fortrea and analytics firms such as Saama are also expanding into the space.
Will AI replace clinical research staff?
Unlikely in the near term. The clearest gains are in tedious, high-volume tasks such as building study databases, validating data, and screening documents. Human judgment remains essential for ethical oversight, safety decisions, and interpreting results. The emerging pattern is a shift in roles rather than a reduction in headcount.
The Road Ahead
The move from single-point tools to unified platforms is the clearest signal yet that AI in clinical trials has matured from experiment to infrastructure. Medidata launching its unified architecture in Shanghai, and IQVIA launching a competing one on the same day, shows how quickly the industry has converged on the same conclusion.
For patients, the promise is practical: fewer failed studies, shorter waits for new treatments, and trials that reach the people who need them. For the industry, the question is no longer whether AI belongs in clinical trials, but who will own the platform that runs them.
